# Outset Medical, Inc.: financial statements, quarterly

OM · Nasdaq · CIK 1484612 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/om.md) · [Financials](/companies/om/financials.md) · [Filings](/companies/om/filings.md) · [Insiders](/companies/om/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/om/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [30.4](/filings/0000950170-24-122518.md) | [30.5 d](/filings/0001193125-26-051278.md) | [28.2](/filings/0000950170-25-066003.md) | [27.4](/filings/0000950170-25-104300.md) | [28.7](/filings/0001193125-25-274504.md) | [29.5 d](/filings/0001193125-26-051278.md) | [29.8](/filings/0001193125-26-212481.md) | [31.4](/filings/0001193125-26-338432.md) | [29.4](/filings/0001193125-25-274504.md) | [28.9 d](/filings/0001193125-26-051278.md) | [27.9](/filings/0001193125-26-212481.md) | [31.6](/filings/0001193125-26-338432.md) |
| Cost of revenue | $m | [23.2](/filings/0000950170-24-122518.md) | [22.8 d](/filings/0001193125-26-051278.md) | [20.0](/filings/0000950170-25-066003.md) | [17.6](/filings/0000950170-25-104300.md) | [18.8](/filings/0001193125-25-274504.md) | [18.7 d](/filings/0001193125-26-051278.md) | [18.7](/filings/0001193125-26-212481.md) | [19.6](/filings/0001193125-26-338432.md) | [17.8](/filings/0001193125-25-274504.md) | [16.6 d](/filings/0001193125-26-051278.md) | [15.8](/filings/0001193125-26-212481.md) | [18.4](/filings/0001193125-26-338432.md) |
| Gross profit | $m | [7.2](/filings/0000950170-24-122518.md) | [7.7 d](/filings/0001193125-26-051278.md) | [8.2](/filings/0000950170-25-066003.md) | [9.8](/filings/0000950170-25-104300.md) | [9.8](/filings/0001193125-25-274504.md) | [10.7 d](/filings/0001193125-26-051278.md) | [11.1](/filings/0001193125-26-212481.md) | [11.9](/filings/0001193125-26-338432.md) | [11.6](/filings/0001193125-25-274504.md) | [12.2 d](/filings/0001193125-26-051278.md) | [12.1](/filings/0001193125-26-212481.md) | [13.3](/filings/0001193125-26-338432.md) |
| Research and development | $m | [16.1](/filings/0000950170-24-122518.md) | [12.5 d](/filings/0001193125-26-051278.md) | [12.6](/filings/0000950170-25-066003.md) | [9.7](/filings/0000950170-25-104300.md) | [8.1](/filings/0001193125-25-274504.md) | [7.9 d](/filings/0001193125-26-051278.md) | [5.5](/filings/0001193125-26-212481.md) | [5.3](/filings/0001193125-26-338432.md) | [5.4](/filings/0001193125-25-274504.md) | [5.1 d](/filings/0001193125-26-051278.md) | [5.6](/filings/0001193125-26-212481.md) | [5.5](/filings/0001193125-26-338432.md) |
| Operating income | $m | [(45.5)](/filings/0000950170-24-122518.md) | [(37.4) d](/filings/0001193125-26-051278.md) | [(36.9)](/filings/0000950170-25-066003.md) | [(30.8)](/filings/0000950170-25-104300.md) | [(23.8)](/filings/0001193125-25-274504.md) | [(21.9) d](/filings/0001193125-26-051278.md) | [(16.4)](/filings/0001193125-26-212481.md) | [(16.9)](/filings/0001193125-26-338432.md) | [(15.8)](/filings/0001193125-25-274504.md) | [(17.6) d](/filings/0001193125-26-051278.md) | [(16.9)](/filings/0001193125-26-212481.md) | [(15.7)](/filings/0001193125-26-338432.md) |
| Interest expense | $m | [3.2](/filings/0000950170-24-122518.md) | [3.4 d](/filings/0001193125-26-051278.md) | [6.0](/filings/0000950170-25-066003.md) | [6.0](/filings/0000950170-25-104300.md) | [6.1](/filings/0001193125-25-274504.md) | [5.8 d](/filings/0001193125-26-051278.md) | [3.6](/filings/0001193125-26-212481.md) | [3.5](/filings/0001193125-26-338432.md) | [3.5](/filings/0001193125-25-274504.md) | [3.4 d](/filings/0001193125-26-051278.md) | [3.4](/filings/0001193125-26-212481.md) | [3.4](/filings/0001193125-26-338432.md) |
| Income tax | $m | [0.1](/filings/0000950170-24-122518.md) | [0.1 d](/filings/0001193125-26-051278.md) | [0.2](/filings/0000950170-25-066003.md) | [0.2](/filings/0000950170-25-104300.md) | [0.2](/filings/0001193125-25-274504.md) | [(0.0) d](/filings/0001193125-26-051278.md) | [0.1](/filings/0001193125-26-212481.md) | [0.1](/filings/0001193125-26-338432.md) | [0.4](/filings/0001193125-25-274504.md) | [0.1 d](/filings/0001193125-26-051278.md) | [0.2](/filings/0001193125-26-212481.md) | [0.2](/filings/0001193125-26-338432.md) |
| Net income | $m | [(46.2)](/filings/0000950170-24-122518.md) | [(38.6) d](/filings/0001193125-26-051278.md) | [(39.9)](/filings/0001193125-25-274504.md) | [(34.5)](/filings/0001193125-25-274504.md) | [(27.9)](/filings/0001193125-25-274504.md) | [(25.6) d](/filings/0001193125-26-051278.md) | [(25.8)](/filings/0001193125-26-338432.md) | [(18.5)](/filings/0001193125-26-338432.md) | [(17.8)](/filings/0001193125-25-274504.md) | [(19.5) d](/filings/0001193125-26-051278.md) | [(19.0)](/filings/0001193125-26-338432.md) | [(18.0)](/filings/0001193125-26-338432.md) |
| Diluted EPS | $ per share | [(0.93)](/filings/0000950170-24-122518.md) | not reported | [(11.77)](/filings/0000950170-25-066003.md) | [(9.96)](/filings/0000950170-25-104300.md) | [(8.02)](/filings/0001193125-25-274504.md) | not reported | [(3.66)](/filings/0001193125-26-212481.md) | [(1.04)](/filings/0001193125-26-338432.md) | [(1.00)](/filings/0001193125-25-274504.md) | not reported | [(1.03)](/filings/0001193125-26-212481.md) | [(0.97)](/filings/0001193125-26-338432.md) |
| Basic EPS | $ per share | [(0.93)](/filings/0000950170-24-122518.md) | not reported | [(11.77)](/filings/0000950170-25-066003.md) | [(9.96)](/filings/0000950170-25-104300.md) | [(8.02)](/filings/0001193125-25-274504.md) | not reported | [(3.66)](/filings/0001193125-26-212481.md) | [(1.04)](/filings/0001193125-26-338432.md) | [(1.00)](/filings/0001193125-25-274504.md) | not reported | [(1.03)](/filings/0001193125-26-212481.md) | [(0.97)](/filings/0001193125-26-338432.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [36.3](/filings/0000950170-24-122518.md) | [68.5](/filings/0000950170-25-030045.md) | [32.2](/filings/0000950170-24-055981.md) | [37.9](/filings/0000950170-24-093071.md) | [33.3](/filings/0000950170-24-122518.md) | [124](/filings/0001193125-26-051278.md) | [75.9](/filings/0000950170-25-066003.md) | [39.6](/filings/0000950170-25-104300.md) | [36.4](/filings/0001193125-25-274504.md) | [35.0](/filings/0001193125-26-338432.md) | [30.6](/filings/0001193125-26-212481.md) | [35.0](/filings/0001193125-26-338432.md) |
| Current assets | $m | [284](/filings/0000950170-23-060476.md) | [291](/filings/0000950170-25-030045.md) | [325](/filings/0000950170-24-055981.md) | [295](/filings/0000950170-24-093071.md) | [275](/filings/0000950170-24-122518.md) | [258](/filings/0001193125-26-051278.md) | [287](/filings/0000950170-25-066003.md) | [276](/filings/0000950170-25-104300.md) | [265](/filings/0001193125-25-274504.md) | [251](/filings/0001193125-26-338432.md) | [237](/filings/0001193125-26-212481.md) | [228](/filings/0001193125-26-338432.md) |
| Total assets | $m | [308](/filings/0000950170-23-060476.md) | [314](/filings/0000950170-25-030045.md) | [346](/filings/0000950170-24-055981.md) | [315](/filings/0000950170-24-093071.md) | [293](/filings/0000950170-24-122518.md) | [276](/filings/0001193125-26-051278.md) | [301](/filings/0000950170-25-066003.md) | [289](/filings/0000950170-25-104300.md) | [277](/filings/0001193125-25-274504.md) | [264](/filings/0001193125-26-338432.md) | [249](/filings/0001193125-26-212481.md) | [242](/filings/0001193125-26-338432.md) |
| Current liabilities | $m | [53.0](/filings/0000950170-23-060476.md) | [55.3](/filings/0000950170-25-030045.md) | [50.7](/filings/0000950170-24-055981.md) | [43.4](/filings/0000950170-24-093071.md) | [42.4](/filings/0000950170-24-122518.md) | [45.4](/filings/0001193125-26-051278.md) | [34.2](/filings/0000950170-25-066003.md) | [36.9](/filings/0000950170-25-104300.md) | [37.4](/filings/0001193125-25-274504.md) | [37.6](/filings/0001193125-26-338432.md) | [37.6](/filings/0001193125-26-212481.md) | [43.9](/filings/0001193125-26-338432.md) |
| Total liabilities | $m | [155](/filings/0000950170-23-060476.md) | [191](/filings/0000950170-25-030045.md) | [253](/filings/0000950170-24-055981.md) | [246](/filings/0000950170-24-093071.md) | [245](/filings/0000950170-24-122518.md) | [249](/filings/0001193125-26-051278.md) | [131](/filings/0000950170-25-066003.md) | [134](/filings/0000950170-25-104300.md) | [135](/filings/0001193125-25-274504.md) | [138](/filings/0001193125-26-338432.md) | [138](/filings/0001193125-26-212481.md) | [146](/filings/0001193125-26-338432.md) |
| Long-term debt | $m | [96.8](/filings/0000950170-23-060476.md) | [130](/filings/0000950170-25-030045.md) | [197](/filings/0000950170-24-055981.md) | [197](/filings/0000950170-24-093071.md) | [197](/filings/0000950170-24-122518.md) | [197](/filings/0001193125-26-051278.md) | [94.1](/filings/0000950170-25-066003.md) | [94.8](/filings/0000950170-25-104300.md) | [95.5](/filings/0001193125-25-274504.md) | [96.2](/filings/0001193125-26-338432.md) | [96.9](/filings/0001193125-26-212481.md) | [97.6](/filings/0001193125-26-338432.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [152](/filings/0000950170-24-122518.md) | [123](/filings/0001193125-26-051278.md) | [93.2](/filings/0001193125-25-274504.md) | [68.6](/filings/0001193125-25-274504.md) | [47.8](/filings/0001193125-25-274504.md) | [26.8](/filings/0001193125-26-338432.md) | [170](/filings/0001193125-26-338432.md) | [155](/filings/0001193125-26-338432.md) | [142](/filings/0001193125-25-274504.md) | [127](/filings/0001193125-26-338432.md) | [112](/filings/0001193125-26-338432.md) | [96.3](/filings/0001193125-26-338432.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(34.0) d](/filings/0000950170-24-122518.md) | [(24.4) d](/filings/0001193125-26-051278.md) | [(45.9)](/filings/0000950170-25-066003.md) | [(33.3) d](/filings/0000950170-25-104300.md) | [(20.6) d](/filings/0001193125-25-274504.md) | [(16.5) d](/filings/0001193125-26-051278.md) | [(25.7)](/filings/0001193125-26-212481.md) | [(4.8) d](/filings/0001193125-26-338432.md) | [(6.3) d](/filings/0001193125-25-274504.md) | [(9.5) d](/filings/0001193125-26-051278.md) | [(12.8)](/filings/0001193125-26-212481.md) | [(9.6) d](/filings/0001193125-26-338432.md) |
| Capital expenditure | $m | [0.8 d](/filings/0000950170-24-122518.md) | [1.1 d](/filings/0001193125-26-051278.md) | [0.4](/filings/0000950170-25-066003.md) | [0.1 d](/filings/0000950170-25-104300.md) | [0.4 d](/filings/0001193125-25-274504.md) | [0.0 d](/filings/0001193125-26-051278.md) | [0.1](/filings/0001193125-26-212481.md) | [0.3 d](/filings/0001193125-26-338432.md) | [0.2 d](/filings/0001193125-25-274504.md) | [0.2 d](/filings/0001193125-26-051278.md) | [0.1](/filings/0001193125-26-212481.md) | [0.1 d](/filings/0001193125-26-338432.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [48.1](/filings/0000950170-23-060476.md) | [48.8](/filings/0000950170-24-055981.md) | [49.0](/filings/0000950170-24-093071.md) | [49.9](/filings/0000950170-24-122518.md) | [3.4](/filings/0000950170-25-066003.md) | [3.5](/filings/0000950170-25-104300.md) | [3.5](/filings/0001193125-25-274504.md) | [7.0](/filings/0001193125-26-212481.md) | [17.7](/filings/0001193125-26-338432.md) | [17.8](/filings/0001193125-25-274504.md) | [18.4](/filings/0001193125-26-212481.md) | [18.6](/filings/0001193125-26-338432.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 18,797,164 at 2026-08-04, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-338432.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.